LXRX Lexicon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LXRX

Price (delayed)

$2.3

Market cap

$1.02B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.15

Enterprise value

$1.03B

?
Relative Growth: Rel. Growth: 25
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 39

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role ...

Highlights
Lexicon Pharmaceuticals's quick ratio has soared by 167% YoY but it has decreased by 39% from the previous quarter
The net income has plunged by 134% from the previous quarter but it has increased by 49% YoY
The company's gross profit fell by 41% QoQ and by 29% YoY
LXRX's revenue is down by 40% from the previous quarter and by 29% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.lexpharma.com
Peers: REGN RARE BMRN ILMN

Key stats

What are the main financial stats of LXRX

LXRX stock price

How has the Lexicon Pharmaceuticals stock price performed over time
Intraday
5.5%
1 week
-0.86%
1 month
-3.36%
1 year
96.58%
YTD
100%
QTD
-4.17%

Financial performance

How have Lexicon Pharmaceuticals's revenue and profit performed over time
Revenue
$41.47M
Gross profit
$41.11M
Operating income
-$54.5M
Net income
-$61.12M
Gross margin
99.1%
Net margin
-147.4%
The net income has plunged by 134% from the previous quarter but it has increased by 49% YoY
The operating income has dropped by 125% since the previous quarter but it has surged by 54% year-on-year
The company's gross profit fell by 41% QoQ and by 29% YoY
LXRX's revenue is down by 40% from the previous quarter and by 29% YoY

Price vs fundamentals

How does LXRX's price correlate with its fundamentals

Growth

What is Lexicon Pharmaceuticals's growth rate over time

Valuation

What is Lexicon Pharmaceuticals stock price valuation
LXRX P/E details
P/E
N/A
P/B
5.85
P/S
24.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.93
The company's EPS has shrunk by 114% QoQ but it has surged by 55% YoY
The P/B is 72% higher than the 5-year quarterly average of 3.4 and 36% higher than the last 4 quarters average of 4.3
Lexicon Pharmaceuticals's equity has increased by 35% YoY but it has decreased by 14% QoQ
LXRX's price to sales (P/S) is 97% less than its 5-year quarterly average of 936.6 but 96% more than its last 4 quarters average of 12.4
LXRX's revenue is down by 40% from the previous quarter and by 29% YoY

Efficiency

How efficient is Lexicon Pharmaceuticals business performance
LXRX's ROIC has plunged by 170% from the previous quarter but it is up by 31% YoY
LXRX's ROA has shrunk by 128% QoQ but it is up by 36% YoY
The company's return on equity has shrunk by 117% QoQ but it has surged by 52% YoY
The company's return on sales rose by 31% YoY

Dividends

What is LXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LXRX.

Financial health

How did Lexicon Pharmaceuticals financials performed over time
Lexicon Pharmaceuticals's quick ratio has soared by 167% YoY but it has decreased by 39% from the previous quarter
The current ratio has contracted by 29% from the previous quarter
LXRX's debt is 71% smaller than its equity
Lexicon Pharmaceuticals's equity has increased by 35% YoY but it has decreased by 14% QoQ
Lexicon Pharmaceuticals's debt to equity has decreased by 33% YoY but it has increased by 21% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.